连日来,在减肥药市场竞争不断加剧的背景下,诺和诺德传来一连串利好消息,公司股价在盘前因此出现大涨逾6%。
上周,诺和诺德在上海进博会上展出了旗舰减肥药Wegovy的口服和注射版本,引发全球投资者高度关注,这反映了市场对公司在减肥药领域的高度期待。与此同时,诺和诺德还宣布与Ascendis Pharma达成合作,开发针对肥胖和糖尿病的长效GLP-1受体激动剂,这再次彰显了公司在该领域的持续布局实力。
更为关键的是,诺和诺德于周一(11月6日)发布了2024年第三季度财报,数据显示公司第三季度营收和净利润均超出市场预期。值得关注的是,第三季度诺和诺德畅销减肥药Wegovy销售额173.04亿丹麦克朗,同比激增79%,好于市场预期,这是公司利润增长的重要动力。随着减肥药需求持续升温,Wegovy未来销量预计将继续攀升,这将有助于支撑公司业绩表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.